SURMOUNT-MAINTAIN completes, testing a step-down dose instead of stopping

A 112-week phase 3b study of tirzepatide — the molecule sold as Mounjaro and Zepbound — has completed after asking a question most weight-loss trials have skipped: what happens if you cut the dose instead of stopping the drug altogether ^[1].

The trial, registered as NCT06047548, enrolled 441 adults with obesity or with overweight plus weight-related health problems at 20 US sites ^[1]. Everyone started on tirzepatide and worked up to their maximum tolerated dose. At week 60, 378 participants were randomly assigned to one of three groups: stay on their maximum tolerated dose, step down to 5 mg, or switch to placebo ^[1]. The study ran a total of 112 weeks ^[1].

Why this design is unusual

Earlier withdrawal studies in this drug class were built around an all-or-nothing choice. They took people who had lost weight on an active drug and moved some of them to placebo, then measured how much weight came back. That tells you the drug works, but it does not tell you whether a smaller amount of drug would do the job once the weight is already off.

SURMOUNT-MAINTAIN adds the middle option. By including a fixed 5 mg arm alongside a maximum-tolerated-dose arm and a placebo arm, the trial is set up to compare three different maintenance strategies head to head in the same randomized population ^[1]. That is the first randomized test of dose reduction rather than discontinuation in this setting.

The gap between the 441 people enrolled and the 378 randomized at week 60 reflects the trial's structure: participants had to get through the roughly 60-week lead-in on tirzepatide before they could be assigned to a maintenance group ^[1]. The sources do not explain why the other participants were not randomized, so the reasons — whether side effects, insufficient weight loss, or dropping out for other reasons — are not yet known.

What the sources do not say

No results have been released. The registry record available here does not include weight change data, side effect rates, or how many people in each group finished the study ^[1]. It also does not say when Lilly plans to present or publish findings, or whether the data will be used to support any change to prescribing information.

So the central question — whether 5 mg holds weight as well as a higher dose, and how both compare to stopping — is unanswered in public as of now.

Why it matters for patients

Maintenance is the part of GLP-1 treatment that US patients hit hardest. Once the weight comes off, people face high monthly costs, periodic supply problems, and side effects that some find wearing over years. A lower maintenance dose would be cheaper in some pricing arrangements and might be easier to tolerate, but only if it actually holds the weight.

Until this trial reports, there is no randomized evidence either way. Clinicians who lower doses today are working from experience and individual judgment, not from a controlled comparison. That is exactly the evidence gap SURMOUNT-MAINTAIN was built to fill.

It is also worth noting what the trial does not cover. It studied tirzepatide only, so the findings will not automatically apply to semaglutide (Ozempic, Wegovy, Rybelsus) or to orforglipron (Foundayo). And a 112-week study, with about a year of randomized maintenance, cannot tell you what happens at year five.

What happens next

The study is complete ^[1]. Under US rules, sponsors generally post summary results on ClinicalTrials.gov within a year of a trial's primary completion date, though extensions and delays are possible ^[1]. A specific date for results, a conference presentation, or a journal publication has not been announced in the available sources.

Patients weighing maintenance options with their own prescribers will not have this data in hand yet.